Suzuki Y et al. |
Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. |
2014 |
Drug Metab. Dispos. |
pmid:24135442
|
Hukkanen J et al. |
The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity. |
2015 |
Br J Clin Pharmacol |
pmid:26095142
|
de Graan AJ et al. |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. |
2015 |
Br J Clin Pharmacol |
pmid:26119961
|
Mannheimer B et al. |
No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. |
2015 |
PLoS ONE |
pmid:25835492
|
Naito T et al. |
CYP3A activity based on plasma 4β-hydroxycholesterol during the early postpartum period has an effect on the plasma disposition of amlodipine. |
2015 |
Drug Metab. Pharmacokinet. |
pmid:26654672
|
Björkhem-Bergman L et al. |
Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26617265
|
Gjestad C et al. |
4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation? |
2016 |
Br J Clin Pharmacol |
pmid:26574235
|
Woolsey SJ et al. |
Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects. |
2016 |
Basic Clin. Pharmacol. Toxicol. |
pmid:26399557
|
Pataj Z et al. |
Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. |
2016 |
J Chromatogr A |
pmid:26607314
|
Hasan M et al. |
Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27565568
|
Vanhove T et al. |
Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. |
2016 |
Br J Clin Pharmacol |
pmid:27501475
|
Aubry AF et al. |
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity. |
2016 |
AAPS J |
pmid:27350147
|
Ishida T et al. |
Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain. |
2016 |
Drug Metab. Pharmacokinet. |
pmid:27236640
|
Xue YJ et al. |
Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. |
2016 |
Bioanalysis |
pmid:26805594
|
Mao J et al. |
Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. |
2017 |
Pharm. Res. |
pmid:28815392
|
Gjestad C et al. |
4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients. |
2017 |
Br J Clin Pharmacol |
pmid:28585378
|
Jiang X et al. |
An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects. |
2017 |
Clin Pharmacol Drug Dev |
pmid:27138546
|
Wollmann BM et al. |
4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State. |
2017 |
Clin Transl Sci |
pmid:27991741
|
Størset E et al. |
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28146606
|
Vanhove T et al. |
Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation. |
2017 |
Br J Clin Pharmacol |
pmid:28603840
|